<?xml version='1.0' encoding='utf-8'?>
<document id="29403573"><sentence text="Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies." /><sentence text="The Medicaid Drug Utilization Review (DUR) program is a 2-phase process conducted by Medicaid state agencies" /><sentence text=" The first phase is a prospective DUR and involves electronically monitoring prescription drug claims to identify prescription-related problems, such as therapeutic duplication, contraindications, incorrect dosage, or duration of treatment" /><sentence text=" The second phase is a retrospective DUR and involves ongoing and periodic examinations of claims data to identify patterns of fraud, abuse, underutilization, drug-drug interaction, or medically unnecessary care, implementing corrective actions when needed" /><sentence text=" The Centers for Medicare &amp; Medicaid Services requires each state to measure prescription drug cost-savings generated from its DUR programs on an annual basis, but it provides no guidance or unified methodology for doing so" /><sentence text="" /><sentence text="To describe and synthesize the methodologies used by states to measure cost-savings using their Medicaid retrospective DUR program in federal fiscal years 2014 and 2015" /><sentence text="" /><sentence text="For each state, the cost-savings methodologies included in the Medicaid DUR 2014 and 2015 reports were downloaded from Medicaid's website" /><sentence text=" The reports were then reviewed and synthesized" /><sentence text=" Methods described by the states were classified according to research designs often described in evaluation textbooks" /><sentence text="" /><sentence text="In 2014, the most often used prescription drugs cost-savings estimation methodology for the Medicaid retrospective DUR program was a simple pre-post intervention method, without a comparison group (ie, 12 states)" /><sentence text=" In 2015, the most common methodology used was a pre-post intervention method, with a comparison group (ie, 14 states)" /><sentence text=" Comparisons of savings attributed to the program among states are still unreliable, because of a lack of a common methodology available for measuring cost-savings" /><sentence text="" /><sentence text="There is great variation among states in the methods used to measure prescription drug utilization cost-savings" /><sentence text=" This analysis suggests that there is still room for improvement in terms of methodology transparency, which is important, because lack of transparency hinders states from learning from each other" /><sentence text=" Ultimately, the federal government needs to evaluate and improve its DUR program" /><sentence text="" /></document>